Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-100 manufacturers

Filters

1 products found

pp-100

Tablets

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
Comments
Indication: Moderate to severe active rheumatoid arthritis and other autoimmune/inflammatory conditions including atopic dermatitis and prurigo nodularis in adult populations Clinical stage: Clinical development — Phase 2 multi‑center trial recruiting with prior Phase 1a/1b studies ongoing Modality: Small molecule protein degrader (Cereblon‑based CDAC) Mechanism / Target: Interleukin‑1 receptor‑associated kinase 4 (IRAK4) degradation to inhibit IL‑1R/TLR signaling and downstream inflammatory pathways Route / form: Oral administration (expected oral small‑molecule formulation) Differentiation: First‑in‑class IRAK4 degrader offering complete elimination of kinase and scaffold function to broadly suppress inflammatory signaling with potential advantages over conventional IRAK4 inhibitors
Manufacturer #38929

Clinical-stage biotech company developing targeted therapies for B-cell malignancies. Focuses on next-generation BTK degraders to overcome resistance to existing inhibitors. Strategy emphasizes global clinical trials and potential commercialization partnerships.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.